Multiple Myeloma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Interleukin-6 prevents dexamethasone-induced myeloma cell death.
|
7949178 |
1994 |
Multiple Myeloma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Molecular analysis of the IL-6 receptor in human multiple myeloma, an IL-6-related disease.
|
8137932 |
1994 |
Multiple Myeloma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
With the use of the CD40 monoclonal antibody (MoAb) G28-5, we examined CD40 expression and the effect of CD40 binding on MM clonogenic colony (MCC) formation to characterize the IL-6/CD40 loop activity in MM.
|
7524765 |
1994 |
Multiple Myeloma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Surprisingly this antagonistic IL-6 variant had an agonistic effect on the human myeloma cell line XG-1, albeit at a 1000-fold higher concentration than wild type IL-6.
|
7578977 |
1995 |
Multiple Myeloma
|
0.400 |
Biomarker
|
disease |
BEFREE |
BMMCs and BMSCs from patients with MM secreted significantly more IL-6 than those from healthy donors (n = 3, P < .001); moreover, after stimulation using CD40L, IL-6 secretion was fourfold greater (n = 3, P < .001) from MM BMMCs and BMSCs than from normal BMMCs and BMSCs.
|
7535594 |
1995 |
Multiple Myeloma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
These data suggest that high levels of IL-6 may contribute to expansion of myeloma clones by inhibiting apoptotic death.
|
7743552 |
1995 |
Multiple Myeloma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Because IL-6 is a critical growth factor in MM, we have examined the IL-6 osteoblastic cell production in our coculture system.
|
7579410 |
1995 |
Multiple Myeloma
|
0.400 |
Biomarker
|
disease |
CTD_human |
Inhibition of PGE2 synthesis (as obtained with indomethacin and the IL-1RA) might be helpful to inhibit myeloma cell proliferation by reducing IL-1-induced endogenous IL-6 production not only in vitro (as demonstrated here) but also in vivo.
|
8520508 |
1995 |
Multiple Myeloma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Based on this observation, the present study developed a new methodology to estimate daily IL-6 production in 13 patients with MM or renal cancer who received anti-IL-6 MoAb.
|
7579407 |
1995 |
Multiple Myeloma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Cytogenetic studies were performed on BM cells after longterm cultures (6 days) with stimulation of cultures by granulocyte-macrophage colony-stimulating factor (GM-CSF), GM-CSF plus interleukin (IL)-6, IL-3 plus IL-6, or GM-CSF plus IL-3 plus IL-6 to improve myeloma cell growth, and 91 patients had an additional unstimulated culture.
|
7537117 |
1995 |
Multiple Myeloma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Recent studies have revealed that interleukin 6 (IL-6) is a growth factor for myeloma, renal cell carcinoma, and certain T-cell lymphomas.
|
7553641 |
1995 |
Multiple Myeloma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Similarly, increased levels of IL-6 have been detected in sera from some patients with multiple myeloma.
|
8579899 |
1995 |
Multiple Myeloma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Our attempts to block MM cell adhesion to BMSC-induced IL-6 secretion by using antibodies to CD29/CDw49d, CD18/11a, and/or CD44 demonstrated minimal effects, suggesting that another ligand-receptor interaction triggers IL-6 secretion when MM cells and BMSCs are juxtaposed.Both MM cells and BMSCs express CD40.
|
8520509 |
1995 |
Multiple Myeloma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Establishment of a novel myeloma cell line KPMM2 carrying t(3;14)(q21;q32), which proliferates specifically in response to interleukin-6 through an autocrine mechanism.
|
7723407 |
1995 |
Multiple Myeloma
|
0.400 |
Biomarker
|
disease |
BEFREE |
IL-6 stimulates proliferation of various tumors, including lymphoma and myeloma; thus, inhibiting IL-6 may decrease the growth of these tumors.
|
7706747 |
1995 |
Multiple Myeloma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The effects of interferon-alpha (IFN-alpha) on the interleukin-6 (IL-6) receptor in a multiple myeloma cell line, U266, have been examined.
|
7619053 |
1995 |
Multiple Myeloma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Interleukin-3 plus interleukin-6 may improve chromosomal analysis of multiple myeloma: cytologic and cytogenetic evidence in thirty-four patients.
|
8830729 |
1996 |
Multiple Myeloma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The cytokine IL-6 has been proposed as an autocrine growth factor in multiple myeloma, and is also required for stimulation of immunoglobulin production and secretion in normal plasma cells and myeloma cells.
|
8726410 |
1996 |
Multiple Myeloma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Establishment and characterization of three myeloma cell lines that demonstrate variable cytokine responses and abilities to produce autocrine interleukin-6.
|
8656685 |
1996 |
Multiple Myeloma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Differential interleukin-6 (IL-6) responses of three established myeloma cell lines in the presence of soluble human IL-6 receptors.
|
8642840 |
1996 |
Multiple Myeloma
|
0.400 |
Biomarker
|
disease |
BEFREE |
It might therefore be possible to develop innovative treatment strategies either to inhibit interleukin 6 production or to interrupt interleukin 6 signal transduction in multiple myeloma.
|
8897437 |
1996 |
Multiple Myeloma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
They also emphasize that all myeloma cell growth factors reported to data involve an activation of the gp130 IL-6 transducer.
|
8916964 |
1996 |
Multiple Myeloma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Electrophoretic mobility shift assays confirmed the involvement of NF-kappa B activation in regulating MM adhesion-induced IL-6 transcription in BMSCs.
|
8562936 |
1996 |
Multiple Myeloma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Anti-IL-6 antibody and IL-6 antisense oligonucleotide suppressed the IL-6 stimulated myeloma cell proliferation, indicating that IL-6 induced the myeloma cell proliferation via an autocrine loop.
|
8640863 |
1996 |
Multiple Myeloma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
These results therefore suggest that anti-Fas MoAb-induced apoptosis in MM cells is associated with activation of SAPK, and that IL-6 may both inhibit apoptosis and modulate SAPK activity.
|
8978296 |
1997 |